Davis, Andrew A.

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 960

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA

Chae, Y. K., Davis, A. A., Carneiro, B. A., Chandra, S., Mohindra, N., Kalyan, A., Kaplan, J., Matsangou, M., Pai, S., Costa, R., et al. (2016) · Oncotarget

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 110

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support

Chae, Y. K., Pan, A. P., Davis, A. A., Patel, S. P., Carneiro, B. A., Kurzrock, R., & Giles, F. J. (2017) · Molecular Cancer Therapeutics

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 70